Investor Center Home

Corporate Profile

Bellicum is a clinical-stage biopharmaceutical company that’s driving the future of cellular immuno-oncology (IO). We discover and develop product candidates in some of the most important areas of cellular immunotherapy, with a focus on CAR-T and CAR-NK therapies.

Bellicum has engineered the newest wave of high-performance cellular technology, unleashing the power of potentially curative IO therapies against a wide range of cancers, providing a better tomorrow for more cancer patients.

Corporate Presentation

View Presentation Corporate Presentation